Effect of breastfeeding and formula feeding on transmission of HIV-1 - A randomized clinical trial

被引:620
作者
Nduati, R
John, G
Mbori-Ngacha, D
Richardson, B
Overbaugh, J
Mwatha, A
Ndinya-Achola, J
Bwayo, J
Onyango, FE
Hughes, J
Kreiss, J
机构
[1] Univ Nairobi, Dept Paediat, Nairobi, Kenya
[2] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Med, Seattle, WA 98195 USA
[5] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[6] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 09期
关键词
D O I
10.1001/jama.283.9.1167
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Transmission of human immunodeficiency virus type 1 (HIV-1) is known to occur through breastfeeding, but the magnitude of risk has not been precisely defined. Whether breast milk HIV-1 transmission risk exceeds the potential risk of formula-associated diarrheal mortality in developing countries is unknown. Objectives To determine the frequency of breast milk transmission of HIV-1 and to compare mortality rates and HIV-1-free survival in breastfed and formula-fed infants. Design and Setting Randomized clinical trial conducted from November 1992 to July 1998 in antenatal clinics in Nairobi, Kenya, with a median follow-up period of 24 months. Participants Of 425 HIV-1-seropositive, antiretroviral-naive pregnant women enrolled, 401 mother-infant pairs were included in the analysis of trial end points. Interventions Mother-infant pairs were randomized to breastfeeding (n = 212) vs formula feeding arms (n = 213). Main Outcome Measures Infant HIV-1 infection and death during the first 2 years of life, compared between the 2 intervention groups. Results Compliance with the assigned feeding modality was 96% in the breastfeeding arm and 70% in the formula arm (P<.001). Median duration of breastfeeding was 17 months. Of the 401 infants included in the analysis, 94% were followed up to HIV-1 infection or mortality end points: 83% for the HIV-1 infection end point and 93% to the mortality end point. The cumulative probability of HIV-1 infection at 24 months was 36.7% (95% confidence interval [CI], 29.4%-44.0%) in the breastfeeding arm and 20.5% (95% CI, 14.0%-27.0%) in the formula arm (P=.001). The estimated rate of breast milk transmission was 16.2% (95% CI, 6.5%-25.9%). Forty-four percent of HIV-1 infection in the breastfeeding arm was attributable to breast milk. Most breast milk transmission occurred early, with 75% of the risk difference between the 2 arms occurring by 6 months, although transmission continued throughout the duration of exposure. The 2-year mortality rates in both arms were similar (breastfeeding arm, 24.4% [95% CI, 18.2%-30.7%] vs formula feeding arm, 20.0% [95% CI, 14.4%-25.6%]; P=.30). The rate of HIV-1-free survival at 2 years was significantly lower in the breastfeeding arm than in the formula feeding arm (58.0% vs 70.0%, respectively; P=.02). Conclusions The frequency of breast milk transmission of HIV-1 was 16.2% in this randomized clinical trial, and the majority of infections occurred early during breastfeeding. The use of breast milk substitutes prevented 44% of infant infections and was associated with significantly improved HIV-1-free survival.
引用
收藏
页码:1167 / 1174
页数:8
相关论文
共 24 条
[1]  
[Anonymous], WKLY EPIDEMIOL REC
[2]   Breastfeeding by HIV-1-infected women and outcome in their infants: a cohort study from Durban, South Africa [J].
Bobat, R ;
Moodley, D ;
Coutsoudis, A ;
Coovadia, H .
AIDS, 1997, 11 (13) :1627-1633
[3]  
BOERMA JT, 1998, AIDS S1, V12, P53
[4]   Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study [J].
Coutsoudis, A ;
Pillay, K ;
Spooner, E ;
Kuhn, L ;
Coovadia, HM .
LANCET, 1999, 354 (9177) :471-476
[5]   6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso:: a double-blind placebo-controlled multicentre trial [J].
Dabis, F ;
Msellati, P ;
Meda, N ;
Welffens-Ekra, C ;
You, B ;
Manigart, O ;
Leroy, V ;
Simonon, A ;
Cartoux, M ;
Combe, P ;
Ouangré, A ;
Ramon, R ;
Ky-Zerbo, O ;
Montcho, C ;
Salamon, R ;
Rouzioux, C ;
Van de Perre, P ;
Mandelbrot, L .
LANCET, 1999, 353 (9155) :786-792
[6]   MOTHER-TO-CHILD TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 - REPORT FROM THE NAIROBI STUDY [J].
DATTA, P ;
EMBREE, JE ;
KREISS, JK ;
NDINYAACHOLA, JO ;
BRADDICK, M ;
TEMMERMAN, M ;
NAGELKERKE, NJD ;
MAITHA, G ;
HOLMES, KK ;
PIOT, P ;
PAMBA, HO ;
PLUMMER, FA .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (05) :1134-1140
[7]   RISK OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMISSION THROUGH BREAST-FEEDING [J].
DUNN, DT ;
NEWELL, ML ;
ADES, AE ;
PECKHAM, CS .
LANCET, 1992, 340 (8819) :585-588
[8]  
FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR, P284
[9]  
HUGHES JP, 1993, INTRO BOOTSTRAP, P141
[10]   Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: Association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency [J].
John, GC ;
Nduati, RW ;
MboriNgacha, D ;
Overbaugh, J ;
Welch, M ;
Richardson, BA ;
NdinyaAchola, J ;
Bwayo, J ;
Krieger, J ;
Onyango, F ;
Kreiss, JK .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :57-62